Por Renan Filho · 2026-10-07
**Lead**
The World Health Organization (WHO) has formally concluded that weight loss injections commonly known as 'jabs' are safe for use in obese teenagers, according to a long‑awaited safety review published this week. The announcement marks a significant shift in global public health guidance and is expected to influence treatment protocols in the United Kingdom, where childhood obesity rates remain stubbornly high. The WHO’s endorsement covers a class of medications called GLP‑1 receptor agonists – originally developed for type 2 diabetes – that have already transformed adult obesity care. Now, the organisation is giving the green light for their application in adolescents aged 12 to 17 who meet strict clinical criteria.
**Context**
Obesity among British teenagers has reached alarming levels. Data from the National Child Measurement Programme consistently show that one in five children in Year 6 are classified as obese, with rates even higher in deprived areas. For years, treatment options for adolescents were largely limited to lifestyle interventions – diet, exercise, and behavioural support – with pharmacological or surgical approaches reserved only for extreme cases. The emergence of GLP‑1 agonists such as semaglutide has offered a new tool, but questions about long‑term safety in developing bodies have kept regulators cautious. The WHO’s comprehensive review examined clinical trial data, real‑world evidence, and adverse event reports from multiple countries, including the UK. The assessment concluded that, when used under appropriate medical supervision and combined with lifestyle modification, the benefits of these medications – including meaningful reductions in body weight and improvements in cardiometabolic markers – outweigh the risks for obese adolescents who have not responded adequately to non‑pharmacological therapies.
The WHO’s decision aligns with earlier moves by the European Medicines Agency and the US Food and Drug Administration, both of which have approved GLP‑1 agonists for paediatric use in specific circumstances. However, the WHO’s global authority means its endorsement carries weight beyond regulatory approval, particularly for low‑ and middle‑income countries where obesity is rising fastest. In the UK, the National Institute for Health and Care Excellence (NICE) has already begun evaluating the evidence for adolescent use, and the WHO announcement is likely to accelerate its appraisal. The NHS currently prescribes semaglutide for adults with obesity through specialist weight management services, but access for teenagers remains patchy and often dependent on local commissioning decisions. The WHO’s safety declaration may encourage a more consistent national approach.
**Analysis**
The implications of this announcement for the United Kingdom are profound. Childhood obesity is not only a health crisis but a driver of lifelong inequalities. Obese adolescents are far more likely to become obese adults, facing increased risks of type 2 diabetes, cardiovascular disease, and mental health problems. By endorsing weight loss jabs for this age group, the WHO is acknowledging that lifestyle changes alone are frequently insufficient. The move reframes obesity as a chronic disease requiring medical intervention, rather than a simple failure of willpower. Yet the decision also sparks debate. Critics point out that long‑term safety data in adolescents remain limited; GLP‑1 agonists have been studied for only a few years in paediatric populations, and concerns about gastrointestinal side effects, gallstones, and potential effects on growth and pubertal development persist. The WHO’s review addressed these issues, concluding that the evidence available to date does not show an unacceptable safety signal, but it also recommended ongoing surveillance.
Moreover, the endorsement comes at a time when the global supply of these medications is already strained by soaring demand from adults. In the UK, the NHS has had to prioritise access for patients with the highest need, and adding adolescents to the eligible pool could further stretch resources. There is also the question of cost: GLP‑1 agonists are expensive, and while the NHS can negotiate bulk prices, widespread adolescent use would require substantial funding. The WHO has stressed that medications should never replace efforts to tackle the root causes of obesity – poor diet, inadequate physical activity, and commercial determinants of health. In the UK, this means that any rollout must be accompanied by sustained investment in school meals, sports facilities, and restrictions on junk food advertising. The WHO’s announcement is a tool, not a panacea.
**Sources**
The information in this article is based on the World Health Organization’s official safety review of GLP‑1 receptor agonists for the treatment of obesity in adolescents, published in October 2026. Additional context draws on data from the UK’s National Child Measurement Programme, NICE guidance on weight management, and previous regulatory decisions by the European Medicines Agency and the US Food and Drug Administration. No direct quotes from WHO officials or other named individuals have been used, in accordance with editorial policy.